Long, uncertain time to market. Extremely high costs. High failure rate. These are still critical risks facing pharmaceutical companies and research entities as they develop essential new medicines. BullFrog AI, an emerging digital biopharma company, is committed to changing that paradigm. Using bfLEAP™ - our proprietary AI/ML analytics platform - we aim to improve drug development and clinical trials through identification of high-value data niches and patient subgroups. This will ultimately lead to implementation of new precision medicine strategies in our disease areas of focus, and improved clinical outcomes for patients. Our mission is to improve lives by identifying critical connections between therapies and highly responsive patients – in less time, with less cost, and more precision. BullFrog’s bfLEAP™ platform is one of the most innovative, technologically advanced analytics engines currently on the market today. It can be leveraged to increase odds of success at any stage of new therapeutics development, enabling precise identification of meaningful insights for more agile drug development. We also know that a company is nothing without its people. At BullFrog, we have an exceptional core team of life science industry leaders, scientific and clinical experts, AI technologists, and corporate advisors, determined to revolutionize drug development. Vin Singh - BullFrog's Founder and CEO Mr. Singh is a dynamic visionary and experienced life sciences executive. He has extensive start-up experience, having founded and built several companies in the life science space - including BullFrog, Next Healthcare Inc., and MaxCyte Inc. Most recently, he led the global cell therapy services business for ThermoFisher Scientific. Vin holds a BS in Electrical Engineering from Rutgers University, a MS in Biomedical Engineering from Rensselaer Polytechnic Institute, and an MBA from Johns Hopkins University. He is known for his strategic thinking, vision, and integrity.